# Treatment Methods for Rheumatoid Arthritis
The treatment of rheumatoid arthritis is aimed at suppressing the inflammatory response, preventing joint damage, and maintaining mobility and quality of life. The modern approach uses various drug classes that intervene in the immune system in different ways. The choice depends on the severity of the disease, whether serious organ involvement is present, how someone responds to previous treatments, and personal factors.
Corticosteroids
Corticosteroids (such as prednisone or methylprednisolone) suppress inflammatory responses by dampening the immune system. These medications work quickly and help bring acute symptoms under control.
ProveniIncluded in official guidelines, or approved by EMA or FDA
Corticosteroids are often used in the acute phase, particularly in combination with other medications. They are usually given in low doses and are intended as a bridge to longer-term treatments. Known side effects include increased susceptibility to infection, weight gain, sleep problems, and with prolonged use osteoporosis (thinning bones). If discontinued after prolonged use, withdrawal symptoms may occur; therefore, tapering always happens under medical supervision.
DMARDs (Synthetic Disease-Modifying Agents)
DMARD stands for 'Disease-Modifying Antirheumatic Drugs'. These medications work by suppressing certain parts of the immune system and can slowly but effectively slow disease progression.
**Methotrexate**
ProveniIncluded in official guidelines, or approved by EMA or FDA
Methotrexate is widely used as a basic treatment. The medication suppresses cell division and works as an anti-inflammatory by interfering with the immune system. It works slowly, and improvement is usually noticed after several weeks to months. Side effects can include nausea, fatigue, reduction in white blood cells (with infection risk), and rarely lung or liver problems. Regular monitoring is necessary.
**Sulfasalazine and Leflunomide**
ProveniIncluded in official guidelines, or approved by EMA or FDA
These medications also work by suppressing certain immune cells. Side effects vary; sulfasalazine can cause stomach complaints and allergic reactions, leflunomide can affect liver values and requires caution in pregnancy.
Biological DMARDs
These medications are made from biological substances and target very specific parts of the inflammatory response. They are typically more powerful than synthetic DMARDs.
**TNF-Alpha Inhibitors (Anti-TNF)**
ProveniIncluded in official guidelines, or approved by EMA or FDA
TNF-alpha is an important inflammatory trigger. Medications such as infliximab, adalimumab, and etanercept bind TNF-alpha and thereby reduce inflammatory activity. This group works faster than many synthetic DMARDs. Side effects include increased susceptibility to infection (tuberculosis is a precaution point), reactions at the injection site, and rarely inflammatory diseases. Regular monitoring is essential.
**IL-6 Inhibitors (Tocilizumab)**
ProveniIncluded in official guidelines, or approved by EMA or FDA
IL-6 is a messenger substance that drives inflammatory responses. Tocilizumab blocks the IL-6 receptor. It is given as an infusion or injection. Side effects compare with TNF inhibitors, including infection risk, and additionally elevated cholesterol levels.
**Abatacept**
ProveniIncluded in official guidelines, or approved by EMA or FDA
Abatacept works by interrupting a signal between immune cells (T-cell co-stimulation inhibition). The medication can be given as an infusion or subcutaneous injection. Side effects involve increased susceptibility to infection, headache, and infusion reactions.
**B-Cell Inhibitors (Rituximab)**
ProveniIncluded in official guidelines, or approved by EMA or FDA
Rituximab targets B-cells, which play a role in the inflammatory response. It is given intravenously, usually in two doses with a two-week interval. Side effects include reactions during the infusion, infections, and reduced sperm count in men. Recent studies compare the efficacy and safety of rituximab and biosimilar variants.
**JAK Inhibitors (Targeted Inhibitors)**
ProveniIncluded in official guidelines, or approved by EMA or FDA
JAK inhibitors block certain signaling pathways in immune cells. Medications such as baricitinib, upadacitinib, and tofacitinib work quickly and can be given orally (unlike many biological agents). Side effects include infection risk, sometimes herpes diseases, and possible effects on blood vessel walls. This drug class has established a strong position in treatment in a short time.
Combination therapy
ProveniIncluded in official guidelines, or approved by EMA or FDA
In many cases, two or more medications are used simultaneously. Methotrexate is often combined with biological agents. Such combinations prove more effective than monotherapy and can provide better long-term results. The risks of side effects increase, which justifies closer monitoring.
Adjustments and discontinuation of biological agents
ProveniIncluded in official guidelines, or approved by EMA or FDA
(for discontinuation under ultrasound guidance)
When a patient is in long-term remission (little to no visible inflammatory activity), a doctor may consider tapering therapy or lowering the dose. This reduces infection risk and cost. However, not everyone tolerates reduction; sometimes the disease flares up. Recent studies, such as RA-BioStop, use ultrasound imaging to more accurately estimate which patients can safely stop their biological medication. Discontinuation always occurs under medical supervision, never on one's own initiative.
Supportive and investigational treatments
**Anti-inflammatory agents for support**
ProveniIncluded in official guidelines, or approved by EMA or FDA
NSAIDs (non-steroidal anti-inflammatory drugs, such as ibuprofen or naproxen) help relieve pain and swelling, but do not slow disease progression. They are usually combined with disease-modifying agents and used short-term, as long-term use can cause gastrointestinal side effects.
**Experimental approaches: microbiota and signal transduction**
ResearchediPositive results in clinical studies, not yet standard treatment
Recent research points to a link between gut bacteria and rheumatoid arthritis. Some substances (ferrostatin, sinomenine) show potential in animal models, and researchers are investigating whether changes in gut flora (via diet, bacteria, or metabolites) can reduce arthritis. These approaches are not yet established in routine practice.
**JAK pathways and inflammatory mediators: new targets**
ResearchediPositive results in clinical studies, not yet standard treatment
Studies on darutiroside and other polypeptides (WMX-8) show inhibition of specific inflammatory pathways in animal models. These agents have not yet reached the phase of clinical practice.
Treatment of organ involvement
In rheumatoid arthritis with damage to other organs (heart, lungs, kidneys), the same biological and synthetic DMARDs are used, though the doctor must be extra careful with certain agents. For example: patients with lung involvement can receive biological agents, but lungs are monitored more closely. Cardiac and renal involvement require clear monitoring before starting some therapies.
Monitoring strategy during intensive treatment
ProveniIncluded in official guidelines, or approved by EMA or FDA
When patients receive biological agents or JAK inhibitors, regular blood tests (blood cell counts, liver values, kidney values) and sometimes ultrasound or CT are needed. This helps detect side effects early and inform treatment decisions. Infectious diseases (tuberculosis, hepatitis) are screened before treatment begins.
---
_This information never replaces a doctor's judgment. Always discuss your situation with your own healthcare provider._